Fourier transform infrared imaging spectroscopy (FTIRI)-assessed bone composition parameters (mineral content, collagen maturity, crystal size and perfection, and carbonate content) describe bone quality and correlate to bone fracture risk. The challenge with studying bone quality in patients treated with antiresorptive drugs such as bisphosphonates (e.g., alendronate) and selective estrogen receptor modulators (SERMs) (e.g. raloxifene) is being able to test bone mechanical performance and material properties pre- and posttreatment. The purpose of this study was to evaluate the FTIRI changes in a large animal model of osteoporosis (female sheep with dietary induced metabolic acidosis; MA). Previous studies have investigated the relationship between bone material properties and bone strength in humans and smaller animals and have shown that changes in compositional properties influence fracture risk. Here we characterize the MA model at 6 and 12 months, demonstrate the loss of bone and changes in compositional properties, and show that 6 months of treatment with both antiresorptives ameliorate the bone loss as assessed by bone mineral density and FTIRI. This preliminary data suggest that the MA sheep model allows investigation of whether drug treatments preserve bone properties that exist at the time of treatment or if they induce further beneficial changes.

Keywords:
Osteoporosis, Antiresorptive treatment, Fourier transform infrared spectroscopy, Sheep
1.
Atti, E., S. Gomez, S.M. Wahl, R. Mendelsohn, E. Paschalis, A.L. Boskey (2002) Effects of transforming growth factor-β deficiency on bone development: a Fourier transform-infrared imaging analysis. Bone 31: 675–684.
2.
Barzel, US (1995) The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. J Bone Miner Res 10: 1431–1436.
3.
Bauer, D.C., D.M. Black, P. Garnero, M. Hochberg, S. Ott, J. Orloff, D.E. Thompson, S.K. Ewing, P.D. Delmas, Fracture Intervention Trial Study Group (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19: 1250–1258.
4.
Bonnelye, E., J.E. Aubin (2005) Estrogen receptor-related receptor alpha: a mediator of estrogen response in bone. J Clin Endocrinol Metab 90: 3115–3121.
5.
Boskey, A.L., R. Coleman (2010) Aging and bone. J Dent Res 89: 1333–1348.
6.
Boskey, A.L., R. Mendelsohn (2005) Infrared spectroscopic characterization of mineralized tissues. Vib Spectrosc 38: 107–114.
7.
Boskey, A.L., L. Spevak, R.S. Weinstein (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20: 793–800.
8.
Cummings, S.R., D. Bates, D.M. Black (2002a) Clinical use of bone densitometry: scientific review. JAMA 288: 1889–1897.
9.
Cummings, S.R., D.B. Karpf, F. Harris, H.K. Genant, K. Ensrud, A.Z. LaCroix, D.M. Black (2002b). Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281–289.
10.
Durchschlag, E., E.P. Paschalis, R. Zoehrer, P. Roschger, P. Fratzl, R. Recker, R. Phipps, K. Klaushofer (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21: 1581–1590.
11.
Faibish, D., S.M. Ott, A.L. Boskey (2006). Mineral changes in osteoporosis: a review. Clin Orthop Relat Res 443: 28–38.
12.
Gadaleta, S.J., E.P. Paschalis, F. Betts, R. Mendelsohn, A.L. Boskey (1996). Fourier transform infrared spectroscopy of the solution-mediated conversion of amorphous calcium phosphate to hydroxyapatite: new correlations between X-ray diffraction and infrared data. Calcif Tissue Int 58: 9–16.
13.
Goldstein, S.A. (1987). The mechanical properties of trabecular bone: dependence on anatomic location and function. J Biomech 20: 1055–1061.
14.
Gourion-Arsiquaud, S., M.R. Allen, D.B. Burr, D. Vashishth, S.Y. Tang, A.L. Boskey (2010) Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46:666–672.
15.
Gourion-Arsiquaud, S., D. Faibish, E. Myers, L. Spevak, J. Compston, A. Hodsman, E. Shane, R.R. Recker, E.R. Boskey, A.L. Boskey (2009) Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture. J Bone Miner Res 24: 1565–1571.
16.
Gourion-Arsiquaud, S., P.A. West, A.L. Boskey (2008). Fourier transform-infrared microspectroscopy and microscopic imaging. Methods Mol Biol 455: 293–303.
17.
Harris, S.S., M.J. Wood, B. Dawson-Hughes (1995) Bone mineral density of the total body and forearm in premenopausal black and white women. Bone 16: S311–S315.
18.
MacLeay, J.M., J.D. Olson, R.M. Ennis, C.M. Les, C.A. Toth, D.L. Wheeler, A.S. Turner (2004a) Dietary-induced metabolic acidosis decreases bone mineral density in mature ovariectomized ewes. Calcif Tissue Int 75: 431–437.
19.
Macleay, J.M., J.D. Olson, A.S. Turner (2004b) Effect of dietary-induced metabolic acidosis and ovariectomy on bone mineral density and markers of bone turnover. J Bone Miner Metab 22: 561–568.
20.
Mendelsohn, R., A.L. Boskey, E.P. Paschalis (2005) Infrared microscopy and imaging of hard and soft tissues: applications to bone, skin, and cartilage; in Levin, R.B.I. (ed): Spectrochemical analysis using infrared multichannel detectors. Ames, Blackwell pp 234–260.
21.
Newman, E., A.S. Turner, J.D. Wark (1995). The potential of sheep for the study of osteopenia: current status and comparison with other animal models. Bone 16: 277S–284S.
22.
Paschalis, E.P., K. Verdelis, S.B. Doty, A.L. Boskey, R. Mendelsohn, M. Yamauchi (2001) Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 16: 1821–1828.
23.
Pienkowski, D., T.M. Doers, M.C. Monier-Faugere, Z. Geng, N.P. Camacho, A.L. Boskey (1997) Calcitonin alters bone quality in beagle dogs. J Bone Miner Res 12: 1936–1943.
24.
Turner, A.S. (2002) The sheep as a model for osteoporosis in humans. Vet J 163: 232–239.
25.
Turner, R.T., A. Maran, S. Lotinun, T. Hefferan, G.L. Evans, M. Zhang, J.D. Sibonga (2001) Animal models for osteoporosis. Rev Endocr Metab Disord 2: 117–127.
26.
Wiederkehr, M., R. Krapf (2001) Metabolic and endocrine effects of metabolic acidosis in humans. Swiss Med Wkly 131: 127–132.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.